# Supplementary table 2 – risk of bias in comparative studies

| **Author** | **Country - Population** | **Exposure groups** | **Pharmaco-economic outcome** | **Bias due to confounding** | **Bias in selection of participants** | **Bias in classification of exposures** | **Bias due to departures from intended exposures** | **Bias due to missing data** | **Bias in measurement of outcomes** | **Bias in selection of the reported result** | **Overall bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Aro, AK.[1] | Finland –  Diabetic patients aged ≥ 65 years | 3 groups: -Good glycemic control -Intermediate glycemic control -Poor glycemic control | EQ-5D index | Serious | No information | Low | Low | Low | Moderate | Moderate | Serious |
| Azmi, S.[2] | Malaysia –  T2DM patients with chronic kidney disease | 2 groups: -With anemia -Without anemia | Direct medical cost | Serious | No information | Moderate | Low | Low | Serious | Moderate | Serious |
| Bar-Oz, D.[3] | Israel –  T2DM patients scheduled for cataract surgery | Pre and post cataract surgery | EQ-5D index | Serious | Low | Low | Low | No information | Moderate | Serious | Serious |
| Budiningsari, D.[4] | Indonesia –  Diabetic patients | 2 groups: -Pictorial dietary assessment tool -Comstock tool | Direct medical cost | Low | Low | Low | Low | Low | Low | Moderate | Moderate |
| Elrayah-Eliadarous, HA.[5] | Sudan – Diabetic patients and participants without diabetes | 2 groups: -With diabetes -Without diabetes | Direct medical and non-medical cost (International Diabetes Federation questionnaire) | Serious | Serious | Moderate | Low | No information | Serious | Moderate | Serious |
| Elrayah-Eliadarous, HA.[5] | Sudan – Diabetic patients and participants without diabetes | 2 groups: -With diabetes -Without diabetes | Being prevented from paid work (International Diabetes Federation questionnaire) | Serious | Serious | Moderate | Low | No information | Serious | Moderate | Serious |
| Emara, KM.[6] | Egypt –  Diabetic patients with charcot neuroarthropathy undergoing tibio-talocalcaneal arthrodesis | Pre and post tibio-talocalcaneal arthrodesis | EQ-5D index | Serious | Low | Low | Low | No information | Moderate | Moderate | Serious |
| Gireesha, KS.[7] | India –  T2DM patients receiving insulin | 2 groups: -Insulin users -Insulin analogs users | EQ-5D index and visual analog scale | Critical | No information | Low | Low | Low | Moderate | Moderate | Critical |
| Icks, A.[8] | Germany –  Diabetic patients | 2 groups: -3-month recall survey -6-month recall survey | Number of physician visits | Low | Low | Low | Low | Low | Low | Moderate | Moderate |
| Janssen, EM.[9] | USA –  T2DM patients | 3 groups: -High school or less -Some college -College or more | Willingness-to-pay | Critical | Moderate | Moderate | Low | Low | Moderate | Moderate | Critical |
| Ji, L.[10] | China –  Diabetic patients receiving insulin by pen injection | 2 groups: -With lipohypertrophy -Without lipohypertrophy | Cost of therapy | Critical | No information | Moderate | Low | Low | Moderate | Moderate | Critical |
| Jiao, F.[11] | China –  Diabetic patients | 2 groups: -Without diabetic complication -With at least one diabetic complication | SF-6D | Moderate | No information | Low | Low | Low | Moderate | Moderate | Moderate |
| Klinge, MW.[12] | Denmark –  Diabetic patients with severe recurrent nausea/vomiting undergoing gastric electrical stimulation | Pre and post gastric electrical stimulation | Cost-utility (SF-6D converted from SF-36) | Serious | Low | Low | Low | Serious | Moderate | Moderate | Serious |
| Kundra, TS.[13] | India –  Diabetic patients undergoing coronary artery bypass grafting | 2 groups: -Prayer sign positive -Prayer sign negative | Hospital length of stay, length of intensive care unit stay, ventilatory hours | Critical | No information | Low | Low | Low | No information | Moderate | Critical |
| Laelasari, E.[14] | Indonesia –  T2DM patients receiving insulin or sulfonylurea | 3 groups: -Insulin -Sulfonylurea -Sulfonylurea + metformin | Direct medical cost | Critical | Low | Low | Low | Low | Low | Moderate | Critical |
| Lee, MH.[15] | Australia –  Diabetic patients and patients without diabetes | 2 groups: -With diabetes -Without diabetes | Hospital length of stay | Serious | Low | Low | Low | Low | Low | Moderate | Serious |
| Lee, Y.[16] | Canada –  T2DM (and pre-T2DM) patients | 2 groups: -Managerial position -Nonmanagerial position | Work productivity (Endicott Work Productivity Scale) | Serious | No information | Moderate | Low | Low | Moderate | Low | Serious |
| Mahdavi, M.[17] | Finland, Germany, Greece, Netherlands, Spain, UK –  T2DM patients | 6 groups: -Regional provider networks from the 6 countries | EQ-5D index | Serious | Serious | Low | Low | Low | Moderate | Moderate | Serious |
| Mapa-Tassou, C.[18] | Cameroun –  T2DM patients and participants without diabetes | 2 groups: -With diabetes -Without diabetes | Use of outpatient and inpatient services and use of medicines | Serious | Serious | Moderate | Low | Low | Serious | Moderate | Serious |
| Markle-Reid, M.[19] | Canada –  T2DM patients aged ≥ 65 years with multiple chronic conditions | 2 groups: -With program -Without program | Direct medical cost (Health and Social Services Utilization Inventory) | Low | Low | Low | Low | Moderate | Moderate | Low | Moderate |
| Modarresnia, L.[20] | Iran –  T2DM patients | 2 groups: -With restless legs syndrome -Without restless legs syndrome | EQ-5D index and visual analog scale | Serious | No information | Low | Low | No information | Moderate | Moderate | Serious |
| Pan, CW.[21] | China –  T2DM patients | 3 groups: -No diabetic retinopathy -Unilateral retinopathy -Bilateral retinopathy | EQ-5D index | Moderate | No information | Low | Low | Low | Moderate | Moderate | Moderate |
| Panisch, S.[22] | Austria –  T2DM patients | 2 groups: -With program -Without program | EQ-5D index and visual analog scale | Low | Low | Low | Low | Low | Moderate | Low | Moderate |
| Riandini, T.[23] | Singapore –  T2DM patients aged ≥ 40 years | 2 groups: -With neuropathy -Without neuropathy | EQ-5D index | Moderate | No information | Low | Low | Low | Moderate | Moderate | Moderate |
| Sankar, V.[24] | India –  Diabetic patients receiving amitriptyline or pregabalin for neuropathy | 2 groups: -Amitriptyline -Pregabalin | Visual analog scale | Critical | No information | Low | Low | Low | Moderate | Moderate | Critical |
| Skordis-Worrall, J.[25] | Kyrgyzstan –  Diabetic patients and tuberculosis patients | 3 groups: -Diabetic patients -Tuberculosis patients -Co-affected patients | Direct medical and non-medical cost | Serious | No information | No information | Low | No information | Serious | Moderate | Serious |
| Soleymanian, T.[26] | Iran –  Patients on maintenance dialysis (diabetic and non-diabetic) | 2 groups: -With diabetes -Without diabetes | Hospitalization rate | Critical | No information | No information | Low | Low | No information | Moderate | Critical |
| Sothornwit, J.[27] | Thailand –  Diabetic patients | 3 groups: -Diabetic foot  -Other diabetic complications -No complication | EQ-5D index | Critical | No information | Low | Low | No information | Moderate | Moderate | Critical |
| Ugurlar, M.[28] | Turkey –  T2DM patients with foot wound undergoing vacuum-assisted closure treatment | 2 groups: -Vacuum-assisted closure (Y-connector) -Vacuum-assisted closure (bridge) | Direct medical cost | Critical | Low | Low | Low | Low | Low | Critical | Critical |
| Xu, RH.[29] | China –  Patients with diabetes, heart disease, hypertension and/or cancer | 4 groups: -With diabetes -With heart disease  -With hypertension  -With cancer | EQ-5D index | Moderate | No information | Moderate | Low | No information | Moderate | Moderate | Moderate |
| Zhu, B.[30] | China –  Diabetic patients with retinopathy undergoing cataract surgery | Pre and post cataract surgery | Cost-utility (Time trade off) | Serious | Low | Low | Low | Low | Moderate | Moderate | Serious |

**References**

1. Aro, A.K., et al., *Glycemic control and health-related quality of life among older home-dwelling primary care patients with diabetes.* Primary Care Diabetes, 2017. **11**(6): p. 577-582.

2. Azmi, S., et al., *The Cost and Quality of Life of Malaysian Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease and Anemia.* Value in Health Regional Issues, 2018. **15**: p. 42-49.

3. Bar-Oz, D., et al., *Glycemic Control and Quality of Life Following Cataract Surgery in Patients with Type 2 Diabetes and without Maculopathy.* Current Eye Research, 2018. **43**(1): p. 96-101.

4. Budiningsari, D., et al., *Evaluation of Pictorial Dietary Assessment Tool for Hospitalized Patients with Diabetes: Cost, Accuracy, and User Satisfaction Analysis.* Nutrients, 2017. **10**(1): p. 28.

5. Elrayah-Eliadarous, H.A., et al., *Economic and social impact of diabetes mellitus in a low-income country: A case-control study in Sudan.* Journal of Diabetes, 2017. **9**(12): p. 1082-1090.

6. Emara, K.M., R. Ahmed Diab, and M. Amr Hemida, *Tibio-calcaneal fusion by retrograde intramedullary nailing in charcot neuroarthropathy.* Foot, 2018. **34**: p. 6-10.

7. Gireesha, K.S. and M. Sumithra, *A prospective study to compare insulin and insulin analogs in type II diabetic patients.* Asian Journal of Pharmaceutical and Clinical Research, 2017. **10**(7): p. 356-359.

8. Icks, A., et al., *Agreement found between self-reported and health insurance data on physician visits comparing different recall lengths.* Journal of Clinical Epidemiology, 2017. **82**: p. 167-172.

9. Janssen, E.M., et al., *Education and patient preferences for treating type 2 diabetes: A stratified discrete-choice experiment.* Patient Preference and Adherence, 2017. **11**: p. 1729-1736.

10. Ji, L., et al., *Lipohypertrophy in China: Prevalence, Risk Factors, Insulin Consumption, and Clinical Impact.* Diabetes Technology and Therapeutics, 2017. **19**(1): p. 61-67.

11. Jiao, F., et al., *Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications.* Health & Quality of Life Outcomes, 2017. **15**(1): p. 13.

12. Klinge, M.W., et al., *Early assessment of cost-effectiveness of gastric electrical stimulation for diabetic nausea and vomiting.* Journal of Neurogastroenterology and Motility, 2017. **23**(4): p. 541-549.

13. Kundra, T.S., P. Kaur, and N. Manjunatha, *Prayer sign as a marker of increased ventilatory hours, length of intensive care unit and hospital stay in patients undergoing coronary artery bypass grafting surgery.* Annals of Cardiac Anaesthesia, 2017. **20**(1): p. 90-92.

14. Laelasari, E., R. Sauriasari, and A. Banun, *Cost-effectiveness analysis of insulin, sulfonylurea, and sulfonylurea- Metformin in type 2 diabetes mellitus.* Asian Journal of Pharmaceutical and Clinical Research, 2017. **10**(Special Issue October): p. 50-53.

15. Lee, M.H., et al., *Factors associated with duration of inpatient hospital stay for patients with diabetes mellitus admitted to a medical unit in a community public hospital.* Australian Journal of Primary Health, 2017. **23**(1): p. 23-30.

16. Lee, Y., et al., *Cognitive Impairment Mediates Workplace Impairment in Persons with Type 2 Diabetes Mellitus: Results From the Motivaction Study.* Canadian Journal of Diabetes., 2017.

17. Mahdavi, M., et al., *The relationship between context, structure, and processes with outcomes of 6 regional diabetes networks in Europe.* PLoS ONE, 2018. **13 (2) (no pagination)**(e0192599).

18. Mapa-Tassou, C., et al., *Use of medical services and medicines attributable to type 2 diabetes care in Yaounde, Cameroon: a cross-sectional study.* BMC health services research, 2017. **17**(1): p. 262.

19. Markle-Reid, M., et al., *Community Program Improves Quality of Life and Self-Management in Older Adults with Diabetes Mellitus and Comorbidity.* Journal of the American Geriatrics Society, 2018. **66**(2): p. 263-273.

20. Modarresnia, L., et al., *Restless Legs Syndrome in Iranian People With Type 2 Diabetes Mellitus: The Role in Quality of Life and Quality of Sleep.* Journal of Clinical Sleep Medicine, 2018. **14**(2): p. 223-228.

21. Pan, C.W., et al., *Diabetic retinopathy and health-related quality of life among Chinese with known type 2 diabetes mellitus.* Quality of Life Research, 2018: p. 1-7.

22. Panisch, S., et al., *The impact of a disease management programme for type 2 diabetes on health-related quality of life: multilevel analysis of a cluster-randomised controlled trial.* Diabetology & metabolic syndrome, 2018. **10**: p. 28.

23. Riandini, T., et al., *Functional status mediates the association between peripheral neuropathy and health-related quality of life in individuals with diabetes.* Acta Diabetologica, 2018. **55**(2): p. 155-164.

24. Sankar, V., et al., *Efficacy, safety and cost effectiveness of amitriptyline and pregabalin in patients with diabetic peripheral neuropathy.* Indian Journal of Pharmaceutical Sciences, 2017. **79**(4): p. 646-650.

25. Skordis-Worrall, J., et al., *Addressing the double-burden of diabetes and tuberculosis: lessons from Kyrgyzstan.* Global Health, 2017. **13**(1): p. 15.

26. Soleymanian, T., et al., *Clinical outcomes and quality of life in hemodialysis diabetic patients versus non-diabetics.* Journal of Nephropathology, 2017. **6**(2): p. 81-89.

27. Sothornwit, J., et al., *Decreased health-related quality of life in patients with diabetic foot problems.* Diabetes, Metabolic Syndrome and Obesity Targets and Therapy, 2018. **11**: p. 35-43.

28. Ugurlar, M., et al., *Comparison of two different vacuum-assisted closure (VAC) treatments of multiple chronic diabetic foot wounds in the same extremity.* Journal of Foot & Ankle Surgery, 2017. **23**(3): p. 173-178.

29. Xu, R.H., A.W.L. Cheung, and E.L.Y. Wong, *Examining the health-related quality of life using EQ-5D-5L in patients with four kinds of chronic diseases from specialist outpatient clinics in Hong Kong SAR, China.* Patient Preference and Adherence, 2017. **11**: p. 1565-1572.

30. Zhu, B., Y. Ma, and H. Zou, *Cost-utility analyses of cataract surgery in vision-threatening diabetic retinopathy.* Journal of Cataract and Refractive Surgery, 2017. **43**(1): p. 95-101.